Where Will Eli Lilly Be in 1 Year?
The company has a looming opportunity to grab the booming GLP-1 agonist market by the horns.
Pharmaceutical powerhouse Eli Lilly (NYSE: LLY) had a banner year in 2024. The company's sales surged 32% to over $45 billion on massive growth from its GLP-1 agonist products, Mounjaro for treating type 2 diabetes and Zepbound for chronic weight management. Due to this growth story, the stock has ripped off over 180% in gains over the past three years.
Lately, however, Eli Lilly's stock has cooled. Shares have been essentially flat since July 2024.
The market for GLP-1 agonists could be evolving, and Eli Lilly has a high-stakes opportunity to dominate it over the coming year. Where might Eli Lilly be in a year, and should investors buy the stock now?
